KRAS G12C in Non-small cell lung cancer
- Primary identifiers
- 7
- Sponsors tracked
- 7
- Evidence types
- 2 of 3
- Last refreshed
- 2026-07-28 · monthly
MightyRayn panel synthesis
OmniRayn’s reading of this landscape — our interpretation, not a registry fact
Covalent KRAS G12C inhibition is past proof and into the combination era: the registry shows the field pairing these agents with checkpoint blockade, EGFR antibodies and MEK inhibition rather than pursuing monotherapy. The literature is explicit that adaptive resistance emerges through pathway rewiring, which is why nearly every active programme here is a combination rather than a single agent. A second wave aimed at other RAS alleles and at the RAS(ON) state appears alongside, suggesting the field treats G12C as a beachhead rather than the destination.
Programs and primary evidence
| Sponsor | Asset | Phase | Mechanism | Primary source |
|---|---|---|---|---|
| Mirati Therapeutics | Adagrasib | 2/3 | covalent KRAS G12C inhibitor, with pembrolizumab |
|
| Merck Sharp & Dohme | Calderasib (MK-1084) | 3 | covalent KRAS G12C inhibitor in the adjuvant setting |
|
| Verastem | Avutometinib + sotorasib | 1/2 | RAF/MEK clamp combined with a G12C inhibitor |
|
| Revolution Medicines | RMC-6291 / RMC-6236 / RMC-9805 | 1/2 | RAS(ON) inhibitors across RAS-mutated disease |
|
| ETOP IBCSG Partners Foundation | Adagrasib | 2 | covalent KRAS G12C inhibitor in an underserved population |
|
| Charite Universitatsmedizin Berlin / UNC Chapel Hill | review | — | resistance drivers and combination strategies |
|
| Germans Trias i Pujol Research Institute | review | — | adaptive resistance via receptor tyrosine kinase rewiring |
|
Method and limits
- Programs are enumerated from primary registries (ClinicalTrials.gov, PubMed). A program appears here only if a primary record links this target to this indication as a therapeutic hypothesis — associations and risk markers are excluded by design.
- Every claim above carries the identifier it rests on. We report what the record states; we do not assert efficacy, and computational findings are pending wet-lab confirmation.
- Absence is not evidence of absence: unregistered, non-US and stealth-stage programs are not visible to these sources.
- This page refreshes monthly (no net-new primary entity in 132 days). Mechanism classifications are our reading of the public record and may be revised.
Want the analysis behind this landscape?
The public page is the map. The full dossier adds differentiation analysis, kill-tests and the whitespace read for this target — the parts we do not publish.